China Antihypertensive Trial in Acute Ischemic Stroke (CATIS)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Soochow University
Information provided by (Responsible Party):
Jiang He, MD, PhD, Tulane University Health Sciences Center
ClinicalTrials.gov Identifier:
NCT01840072
First received: April 13, 2013
Last updated: September 12, 2013
Last verified: September 2013

April 13, 2013
September 12, 2013
August 2009
May 2013   (final data collection date for primary outcome measure)
  • A combination of death within 14 days after randomization and dependency (modified Rankin scale ≥3) at 14 day or at the time of discharge, if that occurred before 14 days. [ Time Frame: 2 weeks ] [ Designated as safety issue: Yes ]
    The assessment using the modified Rankin scale will be obtained on 14 day after the randomization or at the hospital discharge.
  • Neurological dysfunction (NIH Stroke Scale, NIHSS) [ Time Frame: 2 weeks ] [ Designated as safety issue: Yes ]
    Neurological dysfunction assessment using NIHSS will be obtained on 14 day after the randomization or at the hospital discharge.
  • A combined outcome of in-hospital case-fatality rate (within 2-weeks) and dependency (modified Rankin scale >2) [ Time Frame: 2 weeks ] [ Designated as safety issue: Yes ]
    The assessment using the modified Rankin scale will be obtained on 14 day after the randomization or at the hospital discharge.
  • Neurological dysfunction (NIH Stroke Scale, NIHSS) [ Time Frame: 2 weeks ] [ Designated as safety issue: Yes ]
    Neurological dysfunction assessment using NIHSS will be obtained on 14 day after the randomization or at the hospital discharge.
Complete list of historical versions of study NCT01840072 on ClinicalTrials.gov Archive Site
  • Mortality [ Time Frame: 3, 12, and 24 months ] [ Designated as safety issue: No ]
    Those patients who are still alive at hospital discharge will be contacted by telephone to set up a follow-up clinical visit. Information on clinical deaths will be obtained.
  • Recurrent stroke [ Time Frame: 3, 12 and 24 months ] [ Designated as safety issue: No ]
    Those patients who are still alive at hospital discharge will be contacted by telephone to set up a follow-up clinical visit. Information of recurrent stroke will be collected.
  • Other vascular events [ Time Frame: 3, 12 and 24 months ] [ Designated as safety issue: No ]
    Those patients who are still alive at hospital discharge will be contacted by telephone to set up a follow-up clinical visit. Information of vascular events, such as myocardial infarction, will be collected.
  • Long-term neurological and functional status [ Time Frame: 3, 12 and 24 months ] [ Designated as safety issue: No ]
    Those patients who are still alive at hospital discharge will be contacted by telephone to set up a follow-up clinical visit. Neurological and functional assessments including the modified Rankin scale and NIHSS will be performed.
  • Cognitive function [ Time Frame: 3, 12 and 24 months ] [ Designated as safety issue: No ]
    Those patients who are still alive at hospital discharge will be contacted by telephone to set up a follow-up clinical visit. The information on the cognitive function will be obtained.
  • Quality of life [ Time Frame: 3, 12 and 24 months ] [ Designated as safety issue: No ]
    Those patients who are still alive at hospital discharge will be contacted by telephone to set up a follow-up clinical visit. The information on the quality of life will be obtained.
Same as current
Not Provided
Not Provided
 
China Antihypertensive Trial in Acute Ischemic Stroke
Inner Mongolia Stroke Project

We designed a randomized controlled clinical trial to test:

  • The effectiveness of blood pressure reduction among patients with acute ischemic stroke (within 48 hours of onset) on the primary outcome, a combination of death within 14 days after randomization and dependency (modified Rankin scale ≥3) at 14 day or at the time of discharge, if that occurred before 14 days.
  • The effectiveness of blood pressure reduction among patients with acute ischemic stroke (within 48-hours of onset) on secondary outcomes:

    • Combination of all-cause mortality and dependency over 3, 12, and 24 months of follow-up
    • Combined vascular disease events over 3, 12, and 24 months of follow-up (vascular deaths, non-fatal stroke, non-fatal myocardial infarction, coronary revascularization, hospitalized or treated angina, hospitalized or treated congestive heart failure, and hospitalized or treated peripheral arterial disease)
    • Recurrent fatal and non-fatal stroke over 3, 12, and 24 months of follow-up
    • Neurological functional status measured by NIH Stroke Score and modified Rankin scale at 14 day or discharge after randomization, and over 3, 12, and 24 months of follow-up
    • All-cause mortality over 3, 12, and 24 months of follow-up
    • Duration of initial hospitalization
    • Changes in systolic and diastolic blood pressure within 24 hours and over 7 days, and 14 days
Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Treatment
Ischemic Stroke
Other: Active antihypertensive treatment
Initial antihypertensive treatment with angiotensin-converting enzyme inhibitors (Enalapril) and/or calcium channel blockers as second line medication; and/or diuretics as third line medications. Based on patients' baseline BP level, the first-line medication (intravenous Enalapril) can be used alone, or in combination with second-line medication (calcium channel blocker), and third-line medication (diuretics) to achieve the target systolic BP lowering by 10% to 25% within the first 24 hours after randomization and to achieve systolic BP below 140 mm Hg and diastolic BP below 90 mm Hg and maintain this BP level afterwards during the hospitalization.
  • Experimental: Active antihypertensive treatment
    Active antihypertensive treatment
    Intervention: Other: Active antihypertensive treatment
  • No Intervention: Usual care
    Discontinue all home BP medications.
He J, Zhang Y, Xu T, Zhao Q, Wang D, Chen CS, Tong W, Liu C, Xu T, Ju Z, Peng Y, Peng H, Li Q, Geng D, Zhang J, Li D, Zhang F, Guo L, Sun Y, Wang X, Cui Y, Li Y, Ma D, Yang G, Gao Y, Yuan X, Bazzano LA, Chen J; CATIS Investigators. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial. JAMA. 2014 Feb 5;311(5):479-89. doi: 10.1001/jama.2013.282543.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
4071
September 2015
May 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age ≥22 years
  • Ischemic stroke onset within 48 hours confirmed by imaging (CT scan or MRI) study
  • Systolic BP≥140 and <220 mm Hg and diastolic BP≥80 mm Hg
  • No contraindications to antihypertensive treatment
  • Able and willing to sign informed consent by patients or their direct family members

Exclusion Criteria:

  • Individuals with hemorrhagic stroke
  • Individuals with severe heart failure (NY Heart Association class III and IV), myocardial infarction, unstable angina, aortic dissection and cerebrovascular stenosis
  • Individuals in a deep coma
  • Individuals with resistant hypertension [systolic BP ≥170 mm Hg despite use of 4 or more antihypertensive medications for half a year or longer]
  • Intravenous thrombolytic therapy (such as intravenous rtPA)
  • Individuals who are unable to participate in follow-up examination
  • Current pregnant women
Both
22 Years and older
No
Contact information is only displayed when the study is recruiting subjects
China
 
NCT01840072
140815
Yes
Jiang He, MD, PhD, Tulane University Health Sciences Center
Tulane University Health Sciences Center
Soochow University
Principal Investigator: Jiang He, MD, PhD Tulane University SPHTM
Tulane University Health Sciences Center
September 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP